Overcoming Immunological Resistance Enhances the Efficacy of a Novel Anti-tMUC1-CAR T Cell Treatment against Pancreatic Ductal Adenocarcinoma

Chimeric antigen receptor (CAR) T cells have shown remarkable success in treating hematologic cancers. However, this efficacy has yet to translate to treatment in solid tumors. Pancreatic ductal adenocarcinoma (PDA) is a fatal malignancy with poor prognosis and limited treatment options. We have dev...

Volledige beschrijving

Bibliografische gegevens

Hoofdauteurs:	Mahboubeh Yazdanifar, Ru Zhou, Priyanka Grover, Chandra Williams, Mukulika Bose, Laura J. Moore, Shu-ta Wu, John Maher, Didier Dreau, Pinku Mukherjee
Formaat:	Artigo
Taal:	Inglês
Gepubliceerd in:	MDPI AG 2019-09-01
Reeks:	Cells
Onderwerpen:	Immunotherapy targeted therapy pancreatic cancer pancreatic ductal adenocarcinoma CAR T cell engineered T cell MUC1 resistance
Online toegang:	https://www.mdpi.com/2073-4409/8/9/1070
Tags:	Voeg label toe Geen labels, Wees de eerste die dit record labelt!